Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.59 |
| ▸ | MAPT | P10636 | 5/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.56 |
| ▸ | FNTA | P49354 | 1/20 | 0.56 |
| ▸ | FNTB | P49356 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.55 |
| ▸ | AHR | P35869 | 2/20 | 0.55 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28351050 | 0.83 | MAPT (0.64) | MEN1KMT2AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL8792001 | 0.82 | MEN1 (0.58) | MEN1KMT2AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL12691322 | 0.81 | MEN1 (0.65) | MEN1KMT2AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL27477114 | 0.79 | MAPT (0.68) | MEN1KMT2AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL4628084 | 0.79 | MEN1 (0.58) | MEN1KMT2AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL21479833 | 0.79 | MAPT (0.72) | MEN1KMT2AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL29407882 | 0.79 | MAPT (0.72) | MEN1KMT2AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL18381478 | 0.79 | MAPT (0.62) | MEN1KMT2AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL3654754 | 0.79 | MEN1 (0.71) | MEN1KMT2AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL6245320 | 0.78 | MAPT (0.60) | MEN1KMT2AMAPTALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035373-A1 | PROCESSES OF PRODUCING GLUTAMIC ACID COMPOUNDS AND PRODUCTION INTERMEDIATES THEREFORE AND NOVEL INTERMEDIATE FOR THE PROCESSES | AJINOMOTO CO. INC (JP) | 2012-02-09 | — | — | US | disclosed |
| US-7868187-B2 | Processes of producing glutamic acid compounds and production intermediates therefore and novel intermediate for the processes | AJINOMOTO CO., INC. (JP) | 2011-01-11 | — | — | US | disclosed |
| US-7678925-B2 | Processes of producing glutamic acid compounds and production intermediates therefore and novel intermediate for the processes | AJINOMOTO CO., INC. (JP) | 2010-03-16 | — | — | US | disclosed |
| US-20090259052-A1 | PROCESSES OF PRODUCING GLUTAMIC ACID COMPOUNDS AND PRODUCTION INTERMEDIATES THEREFORE AND NOVEL INTERMEDIATE FOR THE PROCESSES | AJINOMOTO CO. INC (JP) | 2009-10-15 | — | — | US | disclosed |
| US-20080091032-A1 | PROCESSES OF PRODUCING GLUTAMIC ACID COMPOUNDS AND PRODUCTION INTERMEDIATES THEREFORE AND NOVEL INTERMEDIATE FOR THE PROCESSES | AJINOMOTO CO. INC (JP) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035373-A1 | PROCESSES OF PRODUCING GLUTAMIC ACID COMPOUNDS AND PRODUCTION INTERMEDIATES THEREFORE AND NOVEL INTERMEDIATE FOR THE PROCESSES | GLUL, MON2, GRIK5 | MEN1 62/4885KMT2A 1562/4885MAPT 1029/4885 |
| US-20080091032-A1 | PROCESSES OF PRODUCING GLUTAMIC ACID COMPOUNDS AND PRODUCTION INTERMEDIATES THEREFORE AND NOVEL INTERMEDIATE FOR THE PROCESSES | GLUL, MON2, GRIK5 | MEN1 62/4885KMT2A 1562/4885MAPT 1029/4885 |
| US-20090259052-A1 | PROCESSES OF PRODUCING GLUTAMIC ACID COMPOUNDS AND PRODUCTION INTERMEDIATES THEREFORE AND NOVEL INTERMEDIATE FOR THE PROCESSES | GLUL, MON2, GRIK5 | MEN1 62/4885KMT2A 1562/4885MAPT 1029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.